Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Mazola

Rank: Vice President [?]

Points: 847 [?]

Votes: 13 Score: 3.0 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer

in response to

Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer

KOO-KOO2

posted on Sep 22, 2020 03:03PM

ZEN-3694 is doing just fine as a cancer treatment with great promise.

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply